Frequently Asked Questions (FAQs)
1. This test is not suggested for screening asymptomatic women 2. CA-125 is elevated in over 90% of patients with advanced ovarian cancer. Many other advanced malignancies can also secrete the CA-125 antigen, such as breast, pancreatic, colon, lung, or liver carcinoma. CA-125 antigen has also been reported to be elevated in non-malignant conditions. 3. Sequential determinations are more useful than a single test, because levels in benign disease do not show significant changes, but a progressive rise occurs in malignant disease. 4. The measurements may also be used to monitor response to chemotherapy. Rising level of CA-125 during chemotherapy is associated with tumor progression and a fall to normal is associated with response. It remains elevated in a stable or progressive serous carcinoma of the ovary. 5. It should be noted that 0.6% of normal women older than 50 years of age have increased levels of CA-125. Normal concentration of CA-125 does not exclude tumor-affected patients.